Servier has nine glioma abstracts for SNO 2026, but can the data expand its treatment reach?
Servier reveals its SNO 2026 plans for Voranigo and Ojemda, with long-term glioma outcomes, treatment durability and potential expansion in focus.
Pharma & Biotech
Pharma & Biotech
Darovasertib worked in metastatic uveal melanoma. Can IDEAYA now stop the cancer from returning?
IDEAYA and Servier begin a 450-patient Phase 3 trial testing whether darovasertib plus crizotinib can prevent uveal melanoma recurrence.
Pharma & Biotech
IDEAYA Biosciences expands ESMO 2026 catalyst slate across eye and lung cancer
IDEAYA Biosciences will use ESMO 2026 to expand the clinical case for darovasertib across three uveal melanoma settings and test the durability of IDE849 responses in small-cell lung cancer.
Pharma & Biotech
Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
Servier is buying sevasemten before pivotal muscular dystrophy data. The deal gives Edgewise cash and investors a sharper cardiology story.
Pharma & Biotech
What to watch as IDEAYA Biosciences reports OptimUM-02 topline results in uveal melanoma
IDEAYA Biosciences will report OptimUM-02 topline data on April 13. Read why this uveal melanoma trial could shift the treatment landscape.
Pharma & Biotech
Why Servier’s $2.5bn acquisition of Day One Biopharmaceuticals could reshape the pediatric glioma treatment landscape
Servier plans a $2.5B acquisition of Day One Biopharmaceuticals to expand its rare oncology pipeline. Discover what the deal means for pediatric glioma.